What Is Somapacitan? Definition and What Research Reports
Somapacitan is a long-acting, albumin-binding derivative of human growth hormone designed for once-weekly rather than daily injection. It is a recombinant protein, not a short synthetic peptide, produced with a small fatty-acid side chain that reversibly binds albumin and slows clearance. Published phase 3 trials in adults and children with growth hormone deficiency reported growth and IGF-I outcomes with weekly administration alongside tolerability data. This entry is definitional only and describes what the literature reports, not how the compound is used.
Definition
Somapacitan is a long-acting derivative of human growth hormone (somatropin) engineered for once-weekly subcutaneous administration instead of the daily injections used with conventional growth hormone. Structurally, it is a recombinant 191-amino-acid growth hormone analogue carrying a single point substitution to which a small albumin-binding side chain (a fatty-acid moiety joined through a hydrophilic linker) is attached. That side chain binds reversibly and non-covalently to circulating albumin, which slows renal filtration and receptor-mediated clearance and extends the molecule's time in circulation. Reviews of its pharmacological profile described it as a growth hormone derivative developed specifically for the treatment of growth hormone deficiency (GHD), with the albumin-binding mechanism as the basis for its extended dosing interval (PMID 41173798, PMID 36305544).
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication.
What Class of Molecule Is It?
Somapacitan sits at the boundary of what people casually call a "peptide." In strict biochemical terms it is a protein therapeutic — a full-length recombinant growth hormone backbone — rather than a short synthetic peptide of a few dozen residues. It is also distinct from growth hormone secretagogues (such as GHRH analogues or ghrelin-receptor agonists), which act upstream by prompting the pituitary to release endogenous growth hormone. Somapacitan is growth hormone itself, chemically modified for persistence.
- Origin: recombinant production, not extraction from tissue.
- Modification: an albumin-binding fatty-acid side chain attached via a linker, the same general half-life-extension chemistry used in several other long-acting biologics.
- Target: the growth hormone receptor, producing downstream insulin-like growth factor I (IGF-I) signalling.
- Administration route studied: subcutaneous injection on a weekly schedule in the published phase 3 programme (PMID 32022863).
How the Term Is Used in the Literature
In research writing, "somapacitan" almost always appears in one of three contexts. First, as a named comparator in trials of growth hormone deficiency, where it is set against daily somatropin. Second, in the broader category of long-acting growth hormone (LAGH) products, where reviews group it with other weekly agents such as somatrogon and lonapegsomatropin; a systematic literature review and network meta-analysis compared somapacitan with those two agents in paediatric GHD (PMID 39261416). Third, in clinical-utility and practice-oriented reviews that summarise how the molecule fits into GHD management (PMID 38333899, PMID 38992799).
Because IGF-I is the standard downstream biomarker of growth hormone action, papers on somapacitan typically report IGF-I standard deviation scores alongside efficacy endpoints; a 3-year analysis of the REAL4 paediatric trial reported efficacy, safety and IGF-I outcomes together for weekly somapacitan in children with growth hormone deficiency (PMID 40400262).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Research Reports
Adults with growth hormone deficiency
A 26-week randomised controlled trial examined the safety and convenience of once-weekly somapacitan in adults with growth hormone deficiency (PMID 29500310). A subsequent randomised phase 3 trial reported that once-weekly somapacitan was effective and well tolerated in adults with growth hormone deficiency (PMID 32022863). A later 24-week randomised active-controlled trial evaluated the efficacy of somapacitan in adult patients with growth hormone deficiency described as experiencing treatment fatigue after previous once-daily growth hormone injections (PMID 40107502).
Children with growth hormone deficiency
The randomised phase 3 REAL4 trial reported that weekly somapacitan was effective and well tolerated in children with growth hormone deficiency (PMID 36062966). Extended follow-up from the same programme reported 3-year efficacy, safety and IGF-I results for weekly somapacitan in that paediatric population (PMID 40400262). A network meta-analysis placed somapacitan alongside somatrogon and lonapegsomatropin for efficacy and safety in paediatric growth hormone deficiency (PMID 39261416).
Children born small for gestational age
Research has extended beyond classic growth hormone deficiency. A randomised controlled phase 3 trial investigated somapacitan in children born small for gestational age (PMID 41782416), and 4-year results from the corresponding phase 2 study in the same population have also been published (PMID 41614610).
Where Somapacitan Appears in the Evidence Base
| Population studied | Study type reported | Reference |
|---|---|---|
| Adults with GHD | 26-week randomised controlled trial (safety, convenience) | PMID 29500310 |
| Adults with GHD | Randomised phase 3 trial | PMID 32022863 |
| Adults with GHD and prior daily injections | 24-week randomised active-controlled trial | PMID 40107502 |
| Children with GHD | Randomised phase 3 trial (REAL4) | PMID 36062966 |
| Children with GHD | 3-year results from REAL4 | PMID 40400262 |
| Children with GHD (indirect comparison) | Systematic review and network meta-analysis | PMID 39261416 |
| Children born small for gestational age | Randomised controlled phase 3 trial | PMID 41782416 |
| Children born small for gestational age | 4-year phase 2 results | PMID 41614610 |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appTolerability: What Studies Report
Tolerability language in the somapacitan literature is generally summarised at the level of the trial conclusion rather than as a list of individual events in the abstracts cited here. The phase 3 adult trial described once-weekly somapacitan as effective and well tolerated in adults with growth hormone deficiency (PMID 32022863), and the REAL4 paediatric trial used the same framing for children with growth hormone deficiency (PMID 36062966). Longer-term safety data in children were reported in the 3-year REAL4 analysis, which paired safety with efficacy and IGF-I outcomes (PMID 40400262). Comparative safety against other long-acting growth hormone products was addressed in the network meta-analysis of paediatric growth hormone deficiency (PMID 39261416). Clinician-facing reviews have discussed monitoring considerations for the molecule in adult growth hormone deficiency (PMID 38992799). Readers looking for full adverse-event tables should consult the primary publications and regulatory labelling rather than summaries.
Regulatory and Contextual Notes
Somapacitan is a prescription biologic product that has been reviewed by regulators for growth hormone deficiency indications; the clinical-utility and pharmacological reviews cited above describe its role in the management of that condition (PMID 38333899, PMID 41173798). It is therefore not in the same regulatory category as research-use-only peptides sold without approval, and the studies summarised here were conducted in diagnosed patient populations under medical supervision, not in healthy volunteers seeking performance or cosmetic outcomes. Researchers have not published, in the literature cited on this page, evidence addressing use outside diagnosed growth hormone deficiency or short stature associated with being born small for gestational age.
Related terms readers often encounter
- Somatropin — recombinant human growth hormone administered daily; the standard comparator in the somapacitan trials (PMID 36062966).
- Somatrogon and lonapegsomatropin — other long-acting growth hormone products compared indirectly with somapacitan in a network meta-analysis (PMID 39261416).
- IGF-I SDS — the standardised biomarker score reported alongside growth outcomes in the 3-year REAL4 analysis (PMID 40400262).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial (The Journal of Clinical Endocrinology and Metabolism, 2022)
- Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial (The Journal of Clinical Endocrinology and Metabolism, 2020)
- Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan (Drug Design, Development and Therapy, 2024)
- A pharmacological profile of somapacitan for the treatment of growth hormone deficiency (Expert Review of Clinical Pharmacology, 2025)
- Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial (European Journal of Endocrinology, 2026)
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis (Advances in Therapy, 2024)
- Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4 (European Journal of Endocrinology, 2025)
- Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency (Drugs of Today, 2022)
- Utilizing Somapacitan, a Long-acting Growth Hormone Formulation, for the Treatment of Adult Growth Hormone Deficiency: A Guide for Clinicians (Endocrine Practice, 2024)
- Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial (European Journal of Endocrinology, 2018)
- Somapacitan in children born small for gestational age: 4-year results from phase 2 (European Journal of Endocrinology, 2026)
- Efficacy of Somapacitan in Treatment-Fatigue Adult Patients With Growth Hormone Deficiency Previously Treated With Once-Daily Growth Hormone Injections: A 24-Week Randomized Active-Controlled Trial (Endocrine Practice, 2025)
Frequently asked questions
Is somapacitan a peptide or a protein?▾
Technically it is a protein therapeutic: a full-length recombinant human growth hormone backbone with an albumin-binding side chain attached, rather than a short synthetic peptide. Reviews of its pharmacological profile described it as a long-acting growth hormone derivative developed for growth hormone deficiency (PMID 41173798, PMID 36305544). It is often discussed in peptide literature because of its shared signalling biology.answer
Why is somapacitan described as long-acting?▾
A fatty-acid side chain attached to the growth hormone backbone binds reversibly to circulating albumin, which slows clearance and lengthens the interval between injections. Pharmacological reviews described this albumin-binding design as the basis of its extended profile in growth hormone deficiency (PMID 41173798, PMID 36305544). Published phase 3 trials studied a once-weekly subcutaneous schedule (PMID 32022863).answer
Which populations have been studied in somapacitan trials?▾
Published trials covered adults with growth hormone deficiency (PMID 32022863, PMID 29500310), children with growth hormone deficiency in the phase 3 REAL4 programme (PMID 36062966), and children born small for gestational age (PMID 41782416, PMID 41614610). These were diagnosed patient populations studied under medical supervision, not healthy volunteers.answer
What did the REAL4 trial report?▾
Researchers reported that weekly somapacitan was effective and well tolerated in children with growth hormone deficiency in the randomised phase 3 REAL4 trial (PMID 36062966). A later analysis reported 3-year efficacy, safety and insulin-like growth factor I outcomes from the same programme (PMID 40400262). The trials compared weekly administration against daily growth hormone.answer
How does somapacitan compare with other long-acting growth hormones?▾
A systematic literature review and network meta-analysis compared somapacitan indirectly with somatrogon and lonapegsomatropin for efficacy and safety in paediatric growth hormone deficiency (PMID 39261416). Network meta-analyses use indirect comparison rather than head-to-head randomisation, so their conclusions carry different weight than a direct trial. Readers should consult the publication for its stated limitations.answer
Is somapacitan an approved medicine or a research chemical?▾
It is a prescription biologic reviewed by regulators for growth hormone deficiency, and clinical-utility reviews have discussed its role in managing that condition (PMID 38333899, PMID 38992799). That places it outside the research-use-only category. This entry is educational only and is not medical advice; questions about treatment belong with a licensed physician.answer
What does the literature say about tolerability?▾
Phase 3 publications described once-weekly somapacitan as effective and well tolerated in adults (PMID 32022863) and in children with growth hormone deficiency (PMID 36062966), and a 3-year analysis reported longer-term safety alongside efficacy and IGF-I data (PMID 40400262). Full adverse-event detail appears in the primary papers and regulatory labelling rather than in summaries.answer
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.